转移性-话题@MedSci

#转移性#

975篇内容 | 3395人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1386596, encodeId=42411386596f5, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=DCR：那不勒斯预后评分是转移性结直肠癌患者有用的预后评价工具, objectType=article, longId=189110, objectId=4dda189110cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dda189110cf, replyNumber=0, likeNumber=61, createdTime=2020-03-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dda189110cf, moduleTitle=DCR：那不勒斯预后评分是转移性结直肠癌患者有用的预后评价工具, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dda189110cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386595, encodeId=6c5313865953c, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=51, createdTime=2020-02-27, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386594, encodeId=06681386594bd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, objectType=article, longId=188492, objectId=cfd518849273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfd518849273, replyNumber=0, likeNumber=75, createdTime=2020-02-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfd518849273, moduleTitle=FDA批准CMN-001治疗晚期转移性肾细胞癌的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfd518849273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386593, encodeId=b6c113865930a, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2020 SoFOG指南：老年转移性结直肠癌的治疗, objectType=article, longId=188373, objectId=629b1883e325, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=629b1883e325, replyNumber=0, likeNumber=24, createdTime=2020-02-20, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=629b1883e325, moduleTitle=2020 SoFOG指南：老年转移性结直肠癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=629b1883e325)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386592, encodeId=d2f41386592db, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, objectType=article, longId=188280, objectId=62191882804d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62191882804d, replyNumber=0, likeNumber=53, createdTime=2020-02-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62191882804d, moduleTitle=CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62191882804d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386591, encodeId=23d51386591bb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, objectType=article, longId=188272, objectId=6dff1882e2d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dff1882e2d8, replyNumber=0, likeNumber=64, createdTime=2020-02-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dff1882e2d8, moduleTitle=Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dff1882e2d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386590, encodeId=c45b1386590f2, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, objectType=article, longId=187963, objectId=d19718e96350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19718e96350, replyNumber=0, likeNumber=56, createdTime=2020-02-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19718e96350, moduleTitle=NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19718e96350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386589, encodeId=a5a8138658965, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：妥卡替尼治疗HER-2转移性乳腺癌, objectType=article, longId=187962, objectId=d5df18e96237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5df18e96237, replyNumber=0, likeNumber=76, createdTime=2020-02-15, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5df18e96237, moduleTitle=NEJM：妥卡替尼治疗HER-2转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5df18e96237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386588, encodeId=bd77138658822, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2019 CUA/CUOG指南：转移性单纯去势和去势敏感型前列腺癌, objectType=article, longId=187754, objectId=47d318e75409, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47d318e75409, replyNumber=0, likeNumber=53, createdTime=2020-02-11, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47d318e75409, moduleTitle=2019 CUA/CUOG指南：转移性单纯去势和去势敏感型前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47d318e75409)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386587, encodeId=449c138658e0f, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=PNAS：Hsp47可作为转移性乳腺癌的治疗靶点, objectType=article, longId=187647, objectId=0a2b18e6477f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a2b18e6477f, replyNumber=0, likeNumber=66, createdTime=2020-02-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a2b18e6477f, moduleTitle=PNAS：Hsp47可作为转移性乳腺癌的治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a2b18e6477f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386586, encodeId=009113865866e, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, objectType=article, longId=187241, objectId=618618e241e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618618e241e2, replyNumber=0, likeNumber=81, createdTime=2020-02-04, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618618e241e2, moduleTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618618e241e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386585, encodeId=ffac138658591, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, objectType=article, longId=187111, objectId=646618e11101, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=646618e11101, replyNumber=0, likeNumber=90, createdTime=2020-02-03, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=646618e11101, moduleTitle=Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=646618e11101)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386584, encodeId=f0591386584d0, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NEJM：转移性黑素瘤患者胃肠道出血-病例报道, objectType=article, longId=186990, objectId=f3ba186990c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3ba186990c8, replyNumber=0, likeNumber=53, createdTime=2020-02-01, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3ba186990c8, moduleTitle=NEJM：转移性黑素瘤患者胃肠道出血-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3ba186990c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386583, encodeId=88f61386583fc, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=65, createdTime=2020-01-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386582, encodeId=720f1386582c7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=叶酸类药物的关键活性代谢产物Arfolitixorin治疗转移性结直肠癌, objectType=article, longId=186791, objectId=6ca4186e91ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ca4186e91ae, replyNumber=0, likeNumber=67, createdTime=2020-01-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ca4186e91ae, moduleTitle=叶酸类药物的关键活性代谢产物Arfolitixorin治疗转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ca4186e91ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386581, encodeId=4af81386581d8, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=2020 ESTRO/EORTC共识建议：寡转移性疾病的特征和分类, objectType=article, longId=186464, objectId=56de186464af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56de186464af, replyNumber=0, likeNumber=33, createdTime=2020-01-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56de186464af, moduleTitle=2020 ESTRO/EORTC共识建议：寡转移性疾病的特征和分类, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56de186464af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386580, encodeId=3203138658002, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, objectType=article, longId=186458, objectId=5e3118645817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e3118645817, replyNumber=0, likeNumber=0, createdTime=2020-01-19, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e3118645817, moduleTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e3118645817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386579, encodeId=f9af13865e954, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=69, createdTime=2020-01-08, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386578, encodeId=64c813865e8d7, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, objectType=article, longId=185333, objectId=36af18533328, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af18533328, replyNumber=0, likeNumber=58, createdTime=2019-12-29, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af18533328, moduleTitle=FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af18533328)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1386577, encodeId=685d13865e788, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, objectTitle=复发/转移性乳腺癌标志物临床应用专家共识（2019年版）, objectType=article, longId=185317, objectId=f21d18531e96, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21d18531e96, replyNumber=0, likeNumber=59, createdTime=2019-12-28, rootId=0, userName=1249842em09(暂无昵称), userId=1ac22500003, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21d18531e96, moduleTitle=复发/转移性乳腺癌标志物临床应用专家共识（2019年版）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21d18531e96)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性

2020-05-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

DCR：那不勒斯预后评分是转移性结直肠癌患者有用的预后评价工具

2020-03-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-02-27

智智灵药 (审核中...)

前往app查看评论内容

#转移性#

FDA批准CMN-001治疗晚期转移性肾细胞癌的IND

2020-02-22

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2020 SoFOG指南：老年转移性结直肠癌的治疗

2020-02-20

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

CheckMate-025的更新结果显示，在晚期或转移性肾细胞癌患者中，接受PD-1单抗Opdivo治疗的患者在五年后还存活的比例为26％

2020-02-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Opdivo联合Yervoy用于先前未治疗的晚期或转移性肾细胞癌患者，在42个月的随访中证明了持续的生存益处

2020-02-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：曲妥珠单抗-美坦新偶联物二线治疗HER-2转移性乳腺癌

2020-02-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：妥卡替尼治疗HER-2转移性乳腺癌

2020-02-15

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2019 CUA/CUOG指南：转移性单纯去势和去势敏感型前列腺癌

2020-02-11

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

PNAS：Hsp47可作为转移性乳腺癌的治疗靶点

2020-02-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请

2020-02-04

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

Lancet oncol：TAS-102联合贝伐珠单抗可明显延长难治性转移性结直肠癌的无进展存活期

2020-02-03

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NEJM：转移性黑素瘤患者胃肠道出血-病例报道

2020-02-01

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-01-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

叶酸类药物的关键活性代谢产物Arfolitixorin治疗转移性结直肠癌

2020-01-28

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

2020 ESTRO/EORTC共识建议：寡转移性疾病的特征和分类

2020-01-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除

2020-01-19

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

FDA接受Sacituzumab Govitecan治疗转移性三阴性乳腺癌的BLA

2019-12-29

1249842em09(暂无昵称) (审核中...)

前往app查看评论内容

#转移性#

复发/转移性乳腺癌标志物临床应用专家共识（2019年版）

2019-12-28

科室
- - 订阅+
  - 更多科室
工具
服务